Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer


Ozaslan E., Topaloglu U. S. , Inanc M., Erdem U. G. , Demir H., Arpaci E., ...More

JOURNAL OF BUON, vol.22, no.4, pp.863-868, 2017 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 4
  • Publication Date: 2017
  • Title of Journal : JOURNAL OF BUON
  • Page Numbers: pp.863-868

Abstract

Purpose: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients.